ライフサイエンスコーパス: topoisomerase inhibitor

1 totoxic agents (antimicrotubule agents and a topoisomerase inhibitor).

2 poside and, unlike podophyllotoxin, a potent topoisomerase inhibitor.

3 tigated toxicological issues often seen with topoisomerase inhibitors.

4 sitivity to alkylating anticancer agents and topoisomerase inhibitors.

5 esses, including ionizing radiation (IR) and topoisomerase inhibitors.

6 d SLFN11 expression predicted sensitivity to topoisomerase inhibitors.

7 vation in response to ionizing radiation and topoisomerase inhibitors.

8 e of further expanding the chemical space of topoisomerase inhibitors.

9 ic stress through a different mechanism than topoisomerase inhibitors.

10 high susceptibility to DNA damage caused by topoisomerase inhibitors.

11 ukemogenesis of thiopurines, with or without topoisomerase inhibitors.

12 othetically potentiate the cytotoxicities of topoisomerase inhibitors.

13 nsensitive to five other previously reported topoisomerase inhibitors.

14 ffect DNA metabolism, such as irradiation or topoisomerase inhibitors.

15 s that can repair damaged DNA resulting from topoisomerase inhibitors and a variety of other DNA-dama

16 of DNA-damaging agents such as temozolomide, topoisomerase inhibitors and radiation in both in vitro

17 ity of several predicted compounds including topoisomerase inhibitors and resveratrol towards breast

18 or maximal induction of apoptosis, including topoisomerase inhibitors and TRAIL.

19 lung cancer cells are largely insensitive to topoisomerase inhibitors, and depletion of PKCdelta can

20 -Ras-independent cells are more sensitive to topoisomerase inhibitors, and depletion of PKCdelta in t

21 mulin, a pleuromutilin, and new nonquinolone topoisomerase inhibitors are attractive possibilities th

22 Topoisomerase inhibitors are important and clinically ef

23 Topoisomerase inhibitors are in common use as chemothera

24 Type II topoisomerase inhibitors are used to treat both tumors a

25 a modified anthraquinone that functions as a topoisomerase inhibitor as well as an alkylating agent.

26 alpha]anthracene (mutagen) and camptothecin (topoisomerase inhibitor), as well as to agents targeting

27 maging agents such as ionizing radiation and topoisomerase inhibitors, but also enhances the toxicity

28 t (HT) analysis is desirable to identify new topoisomerase inhibitors, but standard in vitro assays f

29 cle profiles observed in the potentiation of topoisomerase inhibitors by Chk1 siRNA, which showed mit

30 cent transcription in cells treated with the topoisomerase inhibitor camptothecin (CPT).

31 quitinating FANCD2 and were sensitive to the topoisomerase inhibitor camptothecin, a feature shared o

32 In human cells treated with the topoisomerase inhibitors camptothecin or etoposide (VP-1

33 histiocytic lymphoma cell line U937 and the topoisomerase inhibitors camptothecin, etoposide, and do

34 antly, we demonstrate that DNA damage drugs, topoisomerase inhibitors, can trigger CKI activation to

35 One, sensitive to the topoisomerase inhibitor ciprofloxacin, appears to initia

36 utants to ETX0914 cross-resistant with other topoisomerase inhibitor classes, including the widely us

37 amptothecin and doxorubicin, two widely used topoisomerase inhibitors conferring S and G2 arrest, res

38 Bacterial topoisomerase inhibitors continue to be actively develop

39 We find that S-phase and topoisomerase inhibitors delay both the initiation and t

40 ation of myosin VI in various tumor cells by topoisomerase inhibitors dictates whether knockdown of m

41 A novel class of bacterial type-II topoisomerase inhibitor displaying a spiropyrimidinetrio

42 rate and are significantly more sensitive to topoisomerase inhibitors (especially camptothecin) than

43 ing agents, e.g., cisplatin, and also to DNA topoisomerase inhibitor etoposide (ETO) than A2780.

44 Although treatment with the topoisomerase inhibitor etoposide dramatically enhanced

45 te in mouse liver by up to 900-fold, and the topoisomerase inhibitor etoposide increased transduction

46 e G(2) arrest that occurs in response to the topoisomerase inhibitors etoposide and merbarone.

47 human breast carcinoma cells exposed to the topoisomerase inhibitor, etoposide.

48 Screens for new classes of topoisomerase inhibitors generally employ methods, such

49 Clinically, a large arsenal of topoisomerase inhibitors has been used to suppress DNA r

50 However, topoisomerase inhibitors have little or no antineoplasti

51 Combinations of topoisomerase inhibitors I and II have been found to syn

52 GSK2140944 is a novel bacterial type II topoisomerase inhibitor in development for the treatment

53 ls more susceptible to cell death induced by topoisomerase inhibitors in an oncology drug screening a

54 crosslinker) and camptothecin (CPT, a type 1 topoisomerase inhibitor) in FANCB-defective cells.

55 We report that DNA damage induced by topoisomerase inhibitors, including etoposide (ETO), res

56 Interestingly, topoisomerase inhibitors, including topotecan, were rece

57 frequency and sensitivity to UV radiation or topoisomerase inhibitors is unaltered.

58 eutic efficacy of irinotecan (CPT-11), a DNA topoisomerase inhibitor, is often limited by the inducti

59 Topotecan, a topoisomerase inhibitor, killed both hair cells and prol

60 Thus, the cytotoxicity of this class of topoisomerase inhibitors likely results from a two-step

61 eing well-characterized DNA-damaging agents, topoisomerase inhibitors may evoke a biological response

62 326A mutant cells were modestly sensitive to topoisomerase inhibitors, mice expressing Ctip-S326A pol

63 nd, DeltatopB cells treated with the type II topoisomerase inhibitor novobiocin displayed aberrant ch

64 protein family, we studied the effect of the topoisomerase inhibitors on NaeI-L43K activity.

65 cells to be more sensitive to type I and II topoisomerase inhibitors, Raf inhibitors, and other drug

66 Therefore, topoisomerase inhibitors regulate SAMHD1 and HIV permiss

67 h its dual action as an alkylating agent and topoisomerase inhibitor, represents a novel anti-cancer

68 inhibition of Chk1 sensitizes tumor cells to topoisomerase inhibitors such as camptothecin and doxoru

69 Although topoisomerase inhibitors, such as camptothecin and topot

70 ncer cells to treatment with camptothecin, a topoisomerase inhibitor that induces DNA double-strand b

71 not hypersensitive to camptothecin, a type-1 topoisomerase inhibitor that induces DSBs at replication

72 Bacterial topoisomerase inhibitors that are built on a tetrahydrop

73 Because WRN syndrome cells are sensitive to topoisomerase inhibitors, these observations suggest tha

74 By using topoisomerase inhibitors to alter the balance between su

75 e and temporally limited use of etoposide, a topoisomerase inhibitor, to eliminate encephalitogenic T

76 Some topoisomerase inhibitors trap covalent topoisomerase-DNA

77 loss of BAK1 exhibit an inferior response to topoisomerase inhibitor treatment in the clinic.

78 ce 7-ethyl-10-hydroxycamptothecin (SN-38), a topoisomerase inhibitor used in cancer therapy.

79 optosis induced by imatinib mesylate and the topoisomerase inhibitor VP-16 in LAMA-R cells.

80 Organisms resistant to other topoisomerase inhibitors were not cross-resistant with E

81 response to the perturbations of topology by topoisomerase inhibitors, whereas human cells do not.